Annemieke J.M. Nieuweboer

Author

Also Known As

A J M Nieuweboer, A. Nieuweboer, A.J.M. Nieuweboer, Annemieke J. M. Nieuweboer, Annemieke J.M. Nieuweboer, Annemieke JM Nieuweboer, Annemieke Nieuweboer

Publications

929

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus MC Cancer Institute Sint Franciscus Gasthuis Elisabeth-TweeSteden Ziekenhuis Erasmus University Rotterdam

About

Annemieke J.M. Nieuweboer is an author at Erasmus MC specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	431
2	Biochemistry	1	1	35
3	Cell Biology	1	1	57
4	Cellular Physiology	1	1	57
5	Immunology	1	1	57

Annemieke J.M. Nieuweboer

Publications

699

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells Wendy Onstenk, Anieta M. Sieuwerts, Jaco Kraan, European Urology UrologyOncologyGenitourinary CancerMedicineCirculating Tumor Cells	2015	237
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer Robert J. van Soest, Annemieke J.M. Nieuweboer, Ellen S. de Morrée, European Journal of Cancer UrologyOncologyMedicinePharmacotherapyAnti-cancer Agent	2015	63
<i>CYP3A4</i>Intron 6 C>T SNP (<i>CYP3A4*22</i>) Encodes Lower CYP3A4 Activity in Cancer Patients, as Measured with Probes Midazolam and Erythromycin Laure Elens, Annemieke J.M. Nieuweboer, Stephen Clarke, Pharmacogenomics	2013	59
Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel Annemieke J.M. Nieuweboer, Shuiying Hu, Chunshan Gui, Cancer Research Pharmaceutical SciencePolymer-drug ConjugateMedicinePaclitaxel ClearanceImmunology	2014	57
Combinations of Urinary Biomarkers for Surveillance of Patients with Incident Nonmuscle Invasive Bladder Cancer: The European FP7 UROMOL Project Tahlita C.M. Zuiverloon, Willemien Beukers, Kirstin A. van der Keur, The Journal of Urology	2012	56
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin Laure Elens, Annemieke J.M. Nieuweboer, Stephen Clarke, Pharmacogenetics and Genomics	2013	42
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding Peter de Bruijn, Anne‐Joy M. de Graan, Annemieke J.M. Nieuweboer, Journal of Pharmaceutical and Biomedical Analysis BiochemistryGas ChromatographyMedicinePractical SolutionBioanalysis	2011	35
Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel Bodine P.S. Belderbos, Ronald de Wit, Esther Oomen‐de Hoop, Oncotarget	2017	32
<i>AR</i> splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel Anieta M. Sieuwerts, Wendy Onstenk, Jaco Kraan, Molecular Oncology	2019	29
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy Stefanie Kraff, Annemieke J.M. Nieuweboer, Ron H.J. Mathijssen, Cancer Chemotherapy and Pharmacology Drug SafetyPharmacological StudyPharmacologySingle Sample StrategyWeekly Paclitaxel	2015	22

Page 1